{
  "meta": {
    "title": "51_Pharmacology_Neet_2019",
    "url": "https://brainandscalpel.vercel.app/51-pharmacology-neet-2019-81e3d97d.html",
    "scrapedAt": "2025-11-30T12:58:05.249Z"
  },
  "questions": [
    {
      "text": "Calculate the therapeutic index of a drug whose dose-response curves are plotted as shown below:",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "4"
        },
        {
          "id": 4,
          "text": "8"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>therapeutic index</strong> is <strong>4</strong>.</p>\n<p>In the above graph,</p>\n<p>Median lethal dose (LD50) = 400</p>\n<p>Median effective dose (ED50) = 100</p>\n<p><strong>Therapeutic index (TI)</strong> =<strong> LD50/ED50.</strong></p>\n<p>Hence,</p>\n<p>Therapeutic index (TI ) = 400/100 = 4</p>\n<p>Clinically, the therapeutic range bound by the dose that produces the minimal therapeutic effect and the dose that produces the maximal acceptable adverse effect is more relevant.</p>\n<p> </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/622c455438be4ab480ed5ee698509c1f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2315",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is true regarding the dose-response curve shown in the image below?",
      "choices": [
        {
          "id": 1,
          "text": "C is competitive antagonist"
        },
        {
          "id": 2,
          "text": "C is more potent than A"
        },
        {
          "id": 3,
          "text": "B is more potent than A"
        },
        {
          "id": 4,
          "text": "B is competitive antagonist"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the above image, <strong>drug B</strong> is a <strong>competitive</strong> antagonist.</p>\n<p>In <strong>competitive antagonism,</strong> the DRC is <strong>shifted to the right</strong> whereas in <strong>non-competitive antagonism </strong>the DRC is <strong>flattened</strong>.</p>\n<p>Thus in the above image Drug B is the Competitive antagonist while <strong>drug C</strong> is the <strong>non-competitive</strong> antagonist.</p>\n<p><strong>Potency:</strong></p>\n<ul>\n<li>It is defined as the&nbsp;<strong>amount</strong> of<strong> drug&nbsp;</strong>needed&nbsp;to<strong> produce </strong>a given<strong> response.</strong></li>\n<li>A&nbsp;<strong>highly potent drug</strong>&nbsp;evokes a given&nbsp;<strong>response</strong> at<strong> low concentrations</strong>&nbsp;and vice-versa.</li>\n<li>The&nbsp;<strong>more</strong> the<strong> curve</strong> is on the<strong> left&nbsp;</strong>in a dose-response curve (DRC)<strong>, </strong>the<strong> greater</strong> is its<strong> potency.</strong></li>\n<li>Thus, in the above image, the potency is drug A &gt; drug C &gt; drug B.</li>\n</ul>\n<p><strong>Efficacy:</strong></p>\n<ul>\n<li>It is defined as the<strong>&nbsp;maximum effect produced</strong>&nbsp;by the drug.</li>\n<li>It expresses the effect produced by the receptors when bound by a certain drug.</li>\n<li>In the log dose-response curve, the&nbsp;<strong>perpendicular height</strong>&nbsp;represents the drug efficacy.</li>\n<li>Thus, in the above image, the efficacy is drug A = drug B &gt; drug C.</li>\n</ul>",
      "question_images": [
        "https://daily-rounds-staging.s3.amazonaws.com/uploads/1b116b337c9d4636888a2aa8223e3636.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8346",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following antiglaucoma medications is unsafe in infants?",
      "choices": [
        {
          "id": 1,
          "text": "Timolol"
        },
        {
          "id": 2,
          "text": "Brimonidine"
        },
        {
          "id": 3,
          "text": "Latanoprost"
        },
        {
          "id": 4,
          "text": "Dorzolamide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The use of <strong>brimonidine </strong>is<strong> unsafe </strong>in infants<strong>. </strong>It is an<strong> alpha-2 agonist</strong>&nbsp;that&nbsp;can cross the blood-brain barrier. This&nbsp;may result in <strong>CNS depression</strong> and<strong> apnoea</strong> in neonates. Therefore it is contraindicated&nbsp;in children less than 2 years.</p>\n<p>&alpha;<sub>2</sub>&nbsp;agonists, through the activation of G-protein coupled receptor activation, inhibit the activity of adenylate cyclase. This reduces cAMP and hence reduces aqueous humor production by ciliary action.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4915",
      "difficulty": "medium"
    },
    {
      "text": "Apparent volume of distribution of a drug is very high (6L/kg). Which of the following is true regarding the distribution of that drug?",
      "choices": [
        {
          "id": 1,
          "text": "Highly bound to plasma proteins"
        },
        {
          "id": 2,
          "text": "Confined to vascular compartment"
        },
        {
          "id": 3,
          "text": "Sequestered in body tissues"
        },
        {
          "id": 4,
          "text": "Both A and B"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the present case, the volume of distribution of the drug is 6L/kg (420 L in a normal adult with reference weight 70kg) which is very high when compared to the total body water of 42L. Therefore, it can be implied that the <strong>drug</strong> is having <strong>high sequestration in tissues</strong>.</p>\n<p>The apparent volume of distribution (<strong>V<sub>d</sub></strong>) is an <strong>imaginary volume</strong> throughout which the <strong>drug</strong> is <strong>distributed</strong> if the <strong>plasma concentration</strong> remains <strong>constant</strong>&nbsp;throughout.&nbsp;</p>\n<p><strong>V<sub>d</sub>&nbsp;= Dose administered IV/ plasma concentration</strong></p>\n<p>The difference in the volume of distribution based on drug type:</p>\n<ul>\n<li><strong>Low</strong>&nbsp;<strong>V<sub>d&nbsp;</sub></strong>\n<ul>\n<li>Restricted to the <strong>intravascular</strong> compartment&nbsp;</li>\n<li>Seen in drugs with high molecular weight (e.g., heparin) or <strong>high protein binding</strong> (e.g., warfarin - 9.8L)</li>\n</ul>\n</li>\n<li><strong>Medium</strong>&nbsp;<strong>V<sub>d&nbsp;</sub></strong>\n<ul>\n<li>Lipid insoluble drugs (e.g., gentamicin - 20L) do not enter the cells and are distributed in the extracellular fluid volume</li>\n<li>Small water-soluble molecules (e.g., ethanol - 42L) are distributed in the total body water</li>\n</ul>\n</li>\n<li><strong>High Vd</strong>\n<ul>\n<li>Sequestered and accumulated in the tissues</li>\n<li>Small lipophilic molecules (e.g., chloroquine - 13000L)&nbsp;&nbsp;</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1835",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following phases of  a clinical trial is also referred to as efficacy trial?",
      "choices": [
        {
          "id": 1,
          "text": "Phase 1"
        },
        {
          "id": 2,
          "text": "Phase 2"
        },
        {
          "id": 3,
          "text": "Phase 3"
        },
        {
          "id": 4,
          "text": "Phase 4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Efficacy</strong> and <strong>appropriate dose range</strong> is the main aim of <strong>phase 2</strong> of clinical trials. It is evaluated on a small group of patients with the target disease.</p>\n<p>Phase II of clinical trials involve a <strong>small group</strong> of <strong>patients</strong> (50-500). Most of the <strong>new drugs </strong>will be administered for the<strong> first time </strong>in<strong> patients</strong> with the target disease. The study is designed to obtain <strong>proof of concept&nbsp;</strong>(potential of the drug to treat the disease) and <strong>dose-ranging study</strong> (provides input for choosing the most appropriate dose for phase 3 studies).</p>\n<p><strong>Phase 3</strong> studies are also known as <strong>pivotal</strong> studies as they establish <strong>treatment benefits.</strong></p><hr><h3>Related Pearl: Phases of Clinical Trials</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phase I</strong></p>\n<p>(First in human)</p>\n</td>\n<td>\n<p><strong>Phase II</strong></p>\n<p>(First in patient)</p>\n</td>\n<td>\n<p><strong>Phase III</strong></p>\n<p>(Multisite trial)</p>\n</td>\n<td>\n<p><strong>Phase IV</strong></p>\n<p>(Postmarketing)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>10&ndash;100&nbsp;</p>\n</td>\n<td>\n<p>50 - 500&nbsp;</p>\n</td>\n<td>\n<p>500 - 3000</p>\n</td>\n<td>\n<p>Large or according to study</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually healthy volunteers</p>\n</td>\n<td>\n<p>Patients with the target disease</p>\n</td>\n<td>\n<p>Patients&nbsp; with the target disease</p>\n</td>\n<td>\n<p>Real-world patients</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Open-label study</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Randomized and controlled trial or blinded</p>\n</td>\n<td>\n<p>Usually the observational or open-label</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Human pharmacology and safety</strong>: The study aims at safety and tolerability; PK parameters</p>\n</td>\n<td>\n<p><strong>Therapeutic exploration and dose-ranging</strong>: Efficacy and dose-ranging</p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p><strong>Therapeutic confirmation/comparison</strong>: Indications&nbsp;are finalized and guidelines for therapeutic use are formulated. Monitoring of adverse reactions</p>\n</td>\n<td>\n<p><strong>Postmarketing surveillance/studies</strong>: Drug interactions; long-term or rare side effects</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Extends from Months to 1year</p>\n</td>\n<td>\n<p>1&ndash;2 years</p>\n</td>\n<td>\n<p>3&ndash;5 years</p>\n</td>\n<td>\n<p>Unending, after drug approval</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7210",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is an oral factor Xa inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Bivalirudin"
        },
        {
          "id": 2,
          "text": "Dabigatran"
        },
        {
          "id": 3,
          "text": "Rivaroxaban"
        },
        {
          "id": 4,
          "text": "Enoxaparin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Rivaroxaban </strong>is an<strong>&nbsp;oral direct factor Xa inhibitor.</strong>&nbsp;They represent a new class of oral anticoagulant drugs that <strong>do not require monitoring</strong>.</p>\n<p>This group of drugs inhibit factor Xa in the final common pathway of clotting [conversion of Prothrombin (Factor II) to thrombin (Factor IIa)]. They are given as fixed doses and have a rapid onset of action.</p>\n<p>Oral direct factor Xa inhibitors are <strong>indicated</strong> in:</p>\n<ul>\n<li>Prevention of embolic stroke in patients with atrial fibrillation (without valvular heart disease)</li>\n<li>Venous thromboembolic disease (VTE)</li>\n<li>Postoperative thromboprophylaxis in patients undergoing hip and knee arthroplasty</li>\n</ul><hr><h3>Related Pearl: Classification of Anticoagulants</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b14dd7e06cd44c95a1d5289e3a32ad8ax1280x1944.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Classification of anticoagulants</strong></td>\n</tr>\n<tr>\n<td>1) Vitamin K antagonist</td>\n<td>Warfarin</td>\n</tr>\n<tr>\n<td>2) Direct thrombin inhibitors (DTI)&nbsp;&nbsp;&nbsp;</td>\n<td>\n<p><strong>Parenteral:&nbsp;Monovalent</strong> DTI-&nbsp;Argatroban</p>\n<p><strong>Bivalent</strong> DTI- Lepirudin, Desirudin, Bivalirudin</p>\n<p><strong>Oral</strong>:&nbsp;Dabigatran&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>3) Indirect thrombin inhibitors&nbsp;</td>\n<td>\n<p>Unfractionated heparin</p>\n<p>Low molecular weight heparins:&nbsp;Enoxaparin, Dalteparin, Tinzaparin, Nadroparin</p>\n</td>\n</tr>\n<tr>\n<td>4) Indirect factor Xa inhibitors</td>\n<td>Fondaparinux</td>\n</tr>\n<tr>\n<td>5) <strong>Oral</strong> Direct factor Xa inhibitors</td>\n<td>Rivaro<strong>xa</strong>ban,Api<strong>xa</strong>ban, Edo<strong>xa</strong>ban,Betri<strong>xa</strong>ban</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7540",
      "difficulty": "medium"
    },
    {
      "text": "What is the drug of choice for diphtheria carrier state?",
      "choices": [
        {
          "id": 1,
          "text": "Amoxicillin"
        },
        {
          "id": 2,
          "text": "Erythromycin"
        },
        {
          "id": 3,
          "text": "Rifampicin"
        },
        {
          "id": 4,
          "text": "Tetracycline"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug of choice for <strong>diphtheria carrier</strong> state is <strong>erythromycin</strong>.</p>\n<p>Erythromycin for 7 days is very effective for eradicating the diphtheria carrier state or acute infections.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7539",
      "difficulty": "easy"
    },
    {
      "text": "What is the mechanism of action of oseltamivir and zanamivir?",
      "choices": [
        {
          "id": 1,
          "text": "DNA polymerase inhibition"
        },
        {
          "id": 2,
          "text": "Protein synthesis inhibition"
        },
        {
          "id": 3,
          "text": "Nucleotide analogue"
        },
        {
          "id": 4,
          "text": "Neuraminidase inhibition"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Oseltamivir</strong> and <strong>zanamivir</strong> are <strong>neuraminidase inhibitors</strong>.</p>\n<p>They <strong>competitively</strong> and <strong>reversibly</strong> interact with the enzyme sites to <strong>inhibit</strong> viral <strong>neuraminidase</strong> activity. This interferes with the release of the progeny from infected host cells, halting the spread of infection.</p>\n<p>Early administration&nbsp;<span class=\"fontstyle0\">hastens the resolution of symptoms if given within 48 h of infection. Os</span>eltamivir is given at a dose of&nbsp;<strong>75 mg, BD for 5 days </strong>for the<strong> treatment</strong> of Influenza A and B.</p>\n<p>For <strong>prophylaxis</strong>, it is given at a dose of <strong>75mg, OD</strong> and continued for the duration of exposure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7545",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a synthetic PGF2 alpha derivative used as an abortifacient?",
      "choices": [
        {
          "id": 1,
          "text": "Dinoprost"
        },
        {
          "id": 2,
          "text": "Dinoprostone"
        },
        {
          "id": 3,
          "text": "Misoprostol"
        },
        {
          "id": 4,
          "text": "Carboprost"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Carboprost</strong> is a 15-methyl synthetic<strong> derivative of PGF2 alpha. </strong>It is used as an abortifacient and in refractory PPH.</p>\n<p>Options A: <strong>Dinoprost </strong>is a natural PGF2 alpha preparation.</p>\n<p>Option B: <strong> Dinoprostone </strong>is natural<strong> PGE2</strong> preparation.</p>\n<p>Option C: <strong>Misoprostol</strong> is a synthetic <strong>PGE1</strong> analog. Gemeprost is also a synthetic PGE1 analog.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB1283",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs causes activation of K+-ATP channels?",
      "choices": [
        {
          "id": 1,
          "text": "Nicorandil"
        },
        {
          "id": 2,
          "text": "Molsidomine"
        },
        {
          "id": 3,
          "text": "Isosorbide dinitrate"
        },
        {
          "id": 4,
          "text": "Nitroglycerin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Nicorandil</strong> causes activation of <strong>K<sup>+</sup>-ATP channels.&nbsp;</strong>This leads to the hyperpolarization of the smooth muscle cells leading to <strong>vasodilatation</strong>.</p>\n<p>It also has nitrate like <strong>cGMP dependent action</strong>. Nicorandil dilates both arteries and veins leading to a decrease in afterload and preload of the heart.</p>\n<p>Molsidomine, isosorbide dinitrate, and nitroglycerin are nitrates. They do not act on K-ATP channels.</p><hr><h3>Related Pearl: Anti-anginal drugs</h3><p>Anti-anginal drugs can be divided into the following categories:</p>\n<ul>\n<li><strong>Nitrates</strong> - dilates veins &gt; arteries, reduces preload</li>\n<li><strong>Calcium channel blockers</strong> - blocks L-type calcium channels\n<ul>\n<li>Dihydropyridines - amlodipine, nifedipine</li>\n<li>Non-dihydropyridines - verapamil, diltiazem</li>\n</ul>\n</li>\n<li><strong>Beta-blockers</strong> - decreases heart rate, contractility and oxygen demand</li>\n<li>Other drugs:&nbsp;\n<ul>\n<li><strong>Ranolazine</strong> - late Na<sup>+</sup>&nbsp;channel blocker</li>\n<li><strong>Ivabradine</strong> - inhibit funny currents in SA node</li>\n<li><strong>Nicorandil</strong> - K<sup>+</sup>-ATP channel agonist</li>\n<li><strong>Trimetazidine</strong> - pFOX inhibitor</li>\n<li><strong>Fasudil</strong> - rho-kinase inhibitor</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1440",
      "difficulty": "easy"
    },
    {
      "text": "Most effective antiemetic for chemotherapy-induced vomiting is_________.",
      "choices": [
        {
          "id": 1,
          "text": "Domperidone"
        },
        {
          "id": 2,
          "text": "Tegaserod"
        },
        {
          "id": 3,
          "text": "Granisetron"
        },
        {
          "id": 4,
          "text": "Doxylamine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Among the given options, the most effective antiemetic for <strong>chemotherapy-induced vomiting</strong> is <strong>granisetron. </strong></p>\n<p>Granisetron is a <strong>5HT3 receptor antagonist</strong>. They are the most effective drugs for the treatment of chemotherapy-induced and post-operative nausea and vomiting.</p>\n<p><strong>Palonosetron</strong> is a&nbsp;<strong>second-generation</strong> 5HT<sub>3</sub><sub>&nbsp;</sub>antagonist&nbsp;that has the <strong>highest affinity</strong> for 5HT3 receptors and has the <strong>maximum potency</strong>.&nbsp;It is also the <strong>longest acting</strong>&nbsp;that makes it effective in delayed emesis associated with chemotherapy. Palonosetron has minimal/no propensity to cause QT interval prolongation.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7566",
      "difficulty": "easy"
    },
    {
      "text": "True statement about teduglutide is :",
      "choices": [
        {
          "id": 1,
          "text": "It is a GLP- 2 analogue"
        },
        {
          "id": 2,
          "text": "It’s half life is 6 - 8 hours"
        },
        {
          "id": 3,
          "text": "It is administered orally"
        },
        {
          "id": 4,
          "text": "It is recommended for patients with colorectal cancer"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Teduglutide </strong>is a<strong> GLP-2 analogue.</strong></p>\n<p>It has been recently approved for the <strong>treatment of short bowel syndrome.&nbsp;</strong>Teduglutide binds to enteric neurons and endocrine cells, stimulating the release of a number of hormones such as insulin-like growth factor, this <strong>stimulates mucosal epithelial growth</strong> and enhances fluid absorption.</p>\n<p>The drug has a<strong>&nbsp;t1/2 of 1&ndash;2 hours&nbsp;</strong>and is&nbsp;<strong>administered subcutaneously</strong>&nbsp;once daily. It can potentially cause<strong>&nbsp;bowel cancer,&nbsp;</strong>therefore it is not recommended for patients with active malignancies.</p>\n<p>Note: GLP-1 analogs are used for the treatment of Type II diabetes mellitus.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7560",
      "difficulty": "medium"
    },
    {
      "text": "Cisatracurium is preferred over atracurium because?",
      "choices": [
        {
          "id": 1,
          "text": "It has rapid onset of action"
        },
        {
          "id": 2,
          "text": "It has less depressant action on heart"
        },
        {
          "id": 3,
          "text": "It has short duration of action"
        },
        {
          "id": 4,
          "text": "It causes less release of histamine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Cisatracurium is preferred over atracurium because<strong>&nbsp;</strong>it causes less release of histamine.</p>\n<p>Other options:</p>\n<p>Option A- Cisatracurium has a <strong>slower onset of action</strong></p>\n<p>Option<strong>&nbsp;</strong>B and C- Both atracurium and cisatracurium have <strong>similar duration of action and cardiac action.</strong>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7173",
      "difficulty": "medium"
    },
    {
      "text": "Which one of the following drugs inhibits neutrophil recruitment?",
      "choices": [
        {
          "id": 1,
          "text": "Montelukast"
        },
        {
          "id": 2,
          "text": "Sodium cromolyn"
        },
        {
          "id": 3,
          "text": "Colchicine"
        },
        {
          "id": 4,
          "text": "Febuxostat"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Colchicine</strong> inhibits neutrophil (granulocyte) recruitment.</p>\n<p>Colchicine acts by preventing the polymerisation of microtubules by binding to tubulin. This reduces neutrophil recruitment to inflamed tissue and also decreases the secretion of chemotactic factors by activated neutrophils, thus reducing the inflammatory response overall.</p>\n<p>Colchicine is used in&nbsp;<strong>gout </strong>and <strong>Mediterranean fever. </strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7549",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following fluoroquinolones has maximum bioavailability?",
      "choices": [
        {
          "id": 1,
          "text": "Ciprofloxacin"
        },
        {
          "id": 2,
          "text": "Levofloxacin"
        },
        {
          "id": 3,
          "text": "Gatifloxacin"
        },
        {
          "id": 4,
          "text": "Norfloxacin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Levofloxacin</strong> and <strong>ofloxacin</strong> have the <strong>maximum bioavailability</strong> among fluoroquinolones.&nbsp; Hence, intravenous and oral doses are the same for these drugs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7456",
      "difficulty": "medium"
    },
    {
      "text": "What is the mechanism of triazoles?",
      "choices": [
        {
          "id": 1,
          "text": "Interferes with DNA and RNA synthesis"
        },
        {
          "id": 2,
          "text": "Inhibition of ergosterol synthesis"
        },
        {
          "id": 3,
          "text": "Forms pores in fungal membranes"
        },
        {
          "id": 4,
          "text": "Inhibits epoxidation of squalene in fungi"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Triazoles act by <strong>inhibition of ergosterol synthesis</strong>.</p>\n<p>The&nbsp;azole group&nbsp;<strong>inhibits</strong>&nbsp;the fungal cytochrome P450 enzyme called 14-&alpha;-sterol demethylase and results in an impairment of conversion of <strong>lanosterol to ergosterol</strong>. This results in the depletion of membrane ergosterol.</p>\n<p>Azole antifungals are of two types:</p>\n<ul>\n<li><strong>Imidazoles</strong> - clotrimazole, ketoconazole, luliconazole</li>\n<li><strong>Triazoles</strong> - itraconazole, fluconazole, voriconazole, posaconazole and isavuconazole</li>\n</ul><hr><h3>Related Pearl: Mechanism of action of Antifungal drugs</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e48d5ad74a9b48c6baa33c90914e13cbx1280x2560.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7458",
      "difficulty": "easy"
    },
    {
      "text": "A dermatologist wants to prescribe acitretin to a patient with psoriasis. Which of the following statements is false regarding the drug?",
      "choices": [
        {
          "id": 1,
          "text": "Contraindicated in persons with hyperlipidemia"
        },
        {
          "id": 2,
          "text": "It can cause increased sensitivity to sunlight"
        },
        {
          "id": 3,
          "text": "Female patients should avoid getting pregnant for 6 months after therapy"
        },
        {
          "id": 4,
          "text": "Acitretin has a half life of about 50 hours"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Female patients should <strong>avoid</strong>&nbsp;<strong>conception</strong>&nbsp;for<strong> 3 years</strong> after discontinuing&nbsp;<strong>acitretin</strong> treatment to prevent <strong>retinoid-induced embryopathy.</strong></p>\n<p>Acitretin is approved for use in the <strong>cutaneous</strong> manifestations of <strong>psoriasis.</strong></p>\n<p>Absolute contraindications:</p>\n<ul>\n<li>Pregnant women</li>\n<li>Women who are planning to get pregnant</li>\n<li>Breastfeeding</li>\n</ul>\n<p>Relative contraindications:</p>\n<ul>\n<li>Leukopenia</li>\n<li>Alcoholism</li>\n<li>Hyperlipidemia</li>\n<li>Hypercholesterolemia</li>\n<li>Hypothyroidism</li>\n<li>Significant hepatic or renal disease</li>\n</ul>\n<p>Note: Female patients should <strong>avoid conception</strong> for <strong>1 month</strong> after discontinuation of <strong>isotretinoin</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7464",
      "difficulty": "medium"
    },
    {
      "text": "Cilastatin is administered to prolong the action of which of the following drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Meropenem"
        },
        {
          "id": 2,
          "text": "Imipenem"
        },
        {
          "id": 3,
          "text": "Cefazolin"
        },
        {
          "id": 4,
          "text": "Piperacillin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Cilastatin</strong> is administered to <strong>prolong</strong> the action of <strong>imipenem</strong>.</p>\n<p>Imipenem is rapidly<strong> hydrolyzed</strong> by the enzyme <strong>renal dehydropeptidase</strong>. It is administered with <strong>cilastatin,</strong> a <strong>reversible inhibitor</strong> of dehydropeptidase to <strong>inhibit</strong> the <strong>breakdown</strong> and prolong the action of imipenem.</p>\n<p>Meropenem is not hydrolyzed by renal dehydropeptidase. Cilastatin administration is not necessary with meropenem<strong>.</strong></p><p><span data-preserver-spaces=\"true\">The FDA approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients &ge;18 years. It was previously approved to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7474",
      "difficulty": "easy"
    },
    {
      "text": "What is the drug used to differentiate myasthenia gravis from cholinergic crisis?",
      "choices": [
        {
          "id": 1,
          "text": "Obidoxime"
        },
        {
          "id": 2,
          "text": "Edrophonium"
        },
        {
          "id": 3,
          "text": "Donepezil"
        },
        {
          "id": 4,
          "text": "Atropine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug used to differentiate myasthenia gravis from a cholinergic crisis is <strong>edrophonium.</strong></p>\n<p>Muscle weakness is a common presentation in patients with myasthenia gravis and cholinergic crisis (excessive dose of anti-ChE drugs).&nbsp;Intravenous injection of edrophonium&nbsp;<strong>improves muscular weakness</strong> in a patient with <strong>myasthenia gravis</strong> and not in a case of cholinergic crisis.&nbsp;</p>\n<p>The test used for this differentiation is known as the <strong>edrophonium test.&nbsp;</strong></p>\n<p>Initially, 2 mg is administered; if improvements of symptoms do not occur within 45 seconds, an additional 8 mg can be administered.&nbsp;Improvement of strength is a positive test for myasthenia gravis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7567",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is true about pegylated-filgrastim?",
      "choices": [
        {
          "id": 1,
          "text": "Duration of action is shorter than normal filgrastim"
        },
        {
          "id": 2,
          "text": "Added advantage is that it can be taken orally"
        },
        {
          "id": 3,
          "text": "It should not be administered in sickle cell patients"
        },
        {
          "id": 4,
          "text": "It is not effective in the treatment of severe neutropenia"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Patients with sickle cell anemia should not receive pegylated filgrastim as it can&nbsp;trigger a <strong>sickle cell crisis.</strong></p>\n<p><strong>Filgrastim&nbsp;</strong>is a recombinant human G-CSF (granulocyte colony-stimulating factor). The pegylated forms of filgrastim, pegfilgrastim, and lipefilgrastim, are longer-acting forms. It is administered subcutaneously or by slow intravenous infusion only.</p>\n<p>Indications of recombinant G-CSF:&nbsp; &nbsp;</p>\n<ul>\n<li>Severe neutropenia after autologous hematopoietic stem cell transplantation</li>\n<li>Severe neutropenia after high dose cancer chemotherapy</li>\n<li>Severe congenital neutropenias</li>\n<li>Neutropenia of patients with <strong>AIDS</strong> receiving <strong>zidovudine</strong></li>\n</ul><p>Filgrastim is the first FDA-approved drug to treat patients with radiation-induced myelosuppression and to increase survival in such patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7477",
      "difficulty": "hard"
    },
    {
      "text": "The best approach in the treatment of chronic SIADH is ______",
      "choices": [
        {
          "id": 1,
          "text": "Tolvaptan"
        },
        {
          "id": 2,
          "text": "Reducing fluid intake to <500 ml per day"
        },
        {
          "id": 3,
          "text": "Demeclocycline"
        },
        {
          "id": 4,
          "text": "Fludrocortisone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The best approach in the treatment of <strong>chronic SIADH</strong> is the oral administration of a&nbsp;vaptan&nbsp;like<strong>&nbsp;tolvaptan</strong>, which is a <strong>selective V2 receptor antagonist</strong>. This<strong>&nbsp;</strong>increases urinary water excretion by <strong>blocking</strong> the <strong>antidiuretic effect of AVP</strong>.</p>\n<p>Other <strong>treatment</strong> options <strong>for chronic SIADH</strong> include:</p>\n<ul>\n<li>Fluid intake &lt; 500 ml/day</li>\n<li>Demeclocycline</li>\n<li>Fludrocortisone&nbsp;</li>\n</ul>\n<p>Increased thirst is a frequently observed characteristic of hyponatremia in SIADH.&nbsp;<strong>Fluid restriction</strong> is usually a burden to the patient. It is <strong>unreliable, impractical,</strong> and <strong>slow</strong> to work. As thirst is particularly difficult to suppress, water restriction in SIADH frequently <strong>leads to</strong> <strong>non-compliance</strong> in the long run. Vaptans would be especially suited for the treatment of these patients. <strong>Serum sodium</strong> concentrations are also <strong>corrected by vaptans</strong> and hence, vaptans substantially improve the quality of life in these patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7469",
      "difficulty": "medium"
    },
    {
      "text": "Intravenous mannitol is used in ____?",
      "choices": [
        {
          "id": 1,
          "text": "Pulmonary edema"
        },
        {
          "id": 2,
          "text": "Congestive cardiac failure"
        },
        {
          "id": 3,
          "text": "Acute kidney injury with anuria"
        },
        {
          "id": 4,
          "text": "Glaucoma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Intravenous mannitol is used for the treatment of acute attacks of <strong>glaucoma.</strong></p>\n<p>Uses of mannitol are:</p>\n<ul>\n<li>To reduce cerebral edema and intracranial pressure</li>\n<li>Enhancement of urinary excretion of salicylates, barbiturates, bromides, and lithium</li>\n<li>Diagnosis of bronchial hyperreactivity (inhalation)</li>\n<li>Antihemolytic urological irrigation during transurethral procedures</li>\n<li>Treatment of acute attacks of glaucoma.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7468",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following carbapenems has increased risk of causing seizures?",
      "choices": [
        {
          "id": 1,
          "text": "Meropenem"
        },
        {
          "id": 2,
          "text": "Imipenem"
        },
        {
          "id": 3,
          "text": "Etrapenem"
        },
        {
          "id": 4,
          "text": "Doripenem"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Imipenem</strong> is the carbapenem that is associated with an <strong>increased risk</strong> of causing <strong>seizures,</strong> especially when high doses are given to patients with CNS lesions.</p>\n<p><strong>Excretion</strong> of imipenem is mainly<strong> renal</strong> and <strong>dosage modification</strong> is required to avoid seizures in renal<strong> failure</strong> patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7475",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following helps in maintaining the patency of ductus arteriosus?",
      "choices": [
        {
          "id": 1,
          "text": "PGF2α"
        },
        {
          "id": 2,
          "text": "PGE1"
        },
        {
          "id": 3,
          "text": "PGH2"
        },
        {
          "id": 4,
          "text": "PGI2"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Prostaglandin E1</strong> (PGE1) maintains the <strong>patency</strong> of<strong>&nbsp;ductus arteriosus&nbsp;</strong>(PDA). This is used in term neonates with underlying cyanotic congenital heart disease awaiting surgical intervention as they have duct-dependant circulation.</p>\n<p><strong>Indomethacin</strong>&nbsp;and <strong>Ibuprofen</strong> are the NSAID indicated for <strong>closing</strong> the <strong>ductus arteriosus</strong> in premature infants and neonates.&nbsp;</p><hr><h3>Related Pearl: Action of various prostaglandins on different organs:</h3><table>\n<tbody>\n<tr>\n<td>Organs</td>\n<td><strong>PGE<sub>2</sub></strong></td>\n<td><strong>PGF<sub>2&alpha;</sub></strong></td>\n<td><strong>PGI<sub>2</sub></strong></td>\n<td><strong>TXA<sub>2</sub></strong></td>\n</tr>\n<tr>\n<td><strong>Blood vessel</strong></td>\n<td>Vasodilatation, &darr; BP</td>\n<td>Vasodilatation (mostly),&nbsp;Largerveins constrict, little effect on BP</td>\n<td>Vasodilatation,&nbsp;&darr; &darr; BP</td>\n<td>Vasoconstriction</td>\n</tr>\n<tr>\n<td><strong>Heart</strong></td>\n<td>Weak inotropic, reflexcardiac stimulation</td>\n<td>Weak inotropic</td>\n<td>-</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Platelet</strong></td>\n<td>Variable effect</td>\n<td>-</td>\n<td>Antiaggregatory</td>\n<td>Aggregation &amp; release reaction</td>\n</tr>\n<tr>\n<td><strong>Uterus</strong></td>\n<td>Contraction (in vivo),Softening of cervix</td>\n<td>Contraction (in vivo &amp; in vitro),Softening of cervix</td>\n<td>-</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Bronchi</strong></td>\n<td>Dilatation, Inhibit histamine release</td>\n<td>Constriction</td>\n<td>Dilatation, Inhibit histamine release</td>\n<td>Constriction</td>\n</tr>\n<tr>\n<td><strong>Stomach</strong></td>\n<td>&darr; acid secretion, &uarr; mucus production</td>\n<td>-</td>\n<td>&darr; acid secretion,mucosal vasodilatation</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Intestine</strong></td>\n<td>Contracts longitudinal &amp; relaxes, circular muscles, peristalsis &uarr;, Cl&macr; &amp; water secretion&uarr;</td>\n<td>Spasmogenic, &uarr; fluid &amp; electrolytesecretion (weak)</td>\n<td>Weak spasmogenic, inhibit toxin-induced fluid secretion</td>\n<td>Weak spasmogenic</td>\n</tr>\n<tr>\n<td><strong>Kidney</strong></td>\n<td>Natriuresis,&nbsp;&darr; Cl&macr; reabsorption, inhibit ADH action,vasodilatation, renin release</td>\n<td>-</td>\n<td>Natriuresis, vasodilatation,renin release</td>\n<td>Vasoconstriction</td>\n</tr>\n<tr>\n<td><strong>CNS</strong></td>\n<td>Pyrogenic, variety of effects on i.e. inj.</td>\n<td>-</td>\n<td>-</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Release of NA</strong></td>\n<td>&uarr; or &darr;</td>\n<td>&uarr; or &darr;</td>\n<td>-</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Afferent nerve</strong></td>\n<td>Sensitize to noxious stimuli</td>\n<td>-</td>\n<td>Same as PGE2</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Endocrine</strong></td>\n<td>Release of ant. Pituitaryhormones, steroids, insulin;TSH-like action</td>\n<td>Release of gonadotropins &amp;prolactin</td>\n<td>-</td>\n<td>-</td>\n</tr>\n<tr>\n<td><strong>Metabolism</strong></td>\n<td>Antilipolytic, insulin like action,mobilization of bone Ca<sup>2+</sup></td>\n<td>-</td>\n<td>-</td>\n<td>-</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7425",
      "difficulty": "medium"
    }
  ]
}